Arcadia Historical Cash Flow
| RKDA Stock | USD 6.30 0.21 3.45% |
Analysis of Arcadia Biosciences cash flow over time is an excellent tool to project Arcadia Biosciences future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Non Cash Items of 524 K or Capital Expenditures of 4.8 K as it is a great indicator of Arcadia Biosciences ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Arcadia Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Arcadia Biosciences is a good buy for the upcoming year.
Arcadia |
About Arcadia Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Arcadia balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Arcadia's non-liquid assets can be easily converted into cash.
Arcadia Biosciences Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Depreciation
Depreciation indicates how much of Arcadia Biosciences value has been used up. For tax purposes Arcadia Biosciences can deduct the cost of the tangible assets it purchases as business expenses. However, Arcadia Biosciences must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Capital Expenditures
Capital Expenditures are funds used by Arcadia Biosciences to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Arcadia Biosciences operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Arcadia Biosciences' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Arcadia Biosciences current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.At present, Arcadia Biosciences' Change To Inventory is projected to decrease significantly based on the last few years of reporting. The current year's Other Non Cash Items is expected to grow to about 524 K, whereas Change In Cash is projected to grow to (13.4 M).
Arcadia Biosciences cash flow statement Correlations
Click cells to compare fundamentals
Arcadia Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Arcadia Biosciences cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (1.5M) | (9.8M) | (2.4M) | 1.1M | 444K | 466.2K | |
| Change In Cash | (3.6M) | 7.6M | 12.6M | (8.0M) | (14.1M) | (13.4M) | |
| Stock Based Compensation | 2.3M | 2.0M | 1.5M | 1.1M | 717K | 681.2K | |
| Free Cash Flow | (18.7M) | (32.6M) | (26.9M) | (14.0M) | (15.3M) | (16.1M) | |
| Change In Working Capital | 123K | (11.5M) | (2.9M) | 1.1M | (3.5M) | (3.3M) | |
| Begin Period Cash Flow | 12.0M | 8.4M | 16.0M | 28.7M | 20.6M | 14.0M | |
| Other Cashflows From Financing Activities | 4.5M | 9.5M | (1.1M) | (962K) | (485K) | (460.8K) | |
| Depreciation | 194K | 662K | 1.0M | 479K | 984K | 506.2K | |
| Other Non Cash Items | (299K) | (15.3M) | 492K | (1M) | 499K | 524.0K | |
| Capital Expenditures | 1.5M | 2.3M | 1.0M | 72K | 5K | 4.8K | |
| Total Cash From Operating Activities | (17.2M) | (30.2M) | (25.9M) | (14.0M) | (15.3M) | (16.1M) | |
| Change To Account Receivables | (437K) | (1.1M) | (40K) | 592K | 184K | 193.2K | |
| Net Income | (28.9M) | (6.0M) | (16.1M) | (15.6M) | (14.0M) | (14.7M) | |
| Total Cash From Financing Activities | 22.0M | 20.6M | 21.9M | 4.5M | 5.5M | 5.2M | |
| End Period Cash Flow | 8.4M | 16.0M | 28.7M | 20.6M | 6.5M | 6.2M | |
| Change To Liabilities | 272K | 2.2M | (614K) | (380K) | (437K) | (415.2K) | |
| Sale Purchase Of Stock | 10M | 5.3M | 9.4M | 25.1M | 28.9M | 30.4M | |
| Investments | (6.9M) | 20.1M | 16.6M | 1.4M | (4.1M) | (3.9M) | |
| Total Cashflows From Investing Activities | (6.0M) | (8.4M) | 17.3M | 16.6M | 19.1M | 20.1M | |
| Change To Operating Activities | (55K) | (671K) | (889K) | (1.5M) | (1.3M) | (1.2M) | |
| Change To Netincome | (7.7M) | 10.8M | (14.9M) | (9.3M) | (8.3M) | (7.9M) | |
| Change Receivables | (703K) | 1.1M | (437K) | (1.1M) | (1.0M) | (956.7K) | |
| Cash And Cash Equivalents Changes | 7.1M | 2.9M | (3.6M) | 7.6M | 8.8M | 9.2M | |
| Cash Flows Other Operating | 335K | 6.1M | (67K) | (4.6M) | (4.1M) | (3.9M) | |
| Issuance Of Capital Stock | 17.5M | 8M | 25.1M | 5M | 6.0M | 11.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Arcadia Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Arcadia Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arcadia Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arcadia Biosciences Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Agricultural Products & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcadia Biosciences. If investors know Arcadia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcadia Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.285 | Earnings Share (6.77) | Revenue Per Share 3.802 | Quarterly Revenue Growth (0.04) | Return On Assets (0.39) |
The market value of Arcadia Biosciences is measured differently than its book value, which is the value of Arcadia that is recorded on the company's balance sheet. Investors also form their own opinion of Arcadia Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcadia Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcadia Biosciences' market value can be influenced by many factors that don't directly affect Arcadia Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcadia Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcadia Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcadia Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.